Comparative PK? [Study Per­for­mance]

posted by Helmut Homepage – Vienna, Austria, 2021-05-12 13:25 (1020 d 05:57 ago) – Posting: # 22345
Views: 1,835

Hi PVRC,

❝ […] the agency …


May I ask: Which agency?

❝ … recommend to demonstrate comparative PK in the absence of bioequivalence.


Do I get you right: The study was planned to demonstrate BE, failed, and now you were asked about ‘comparative PK’? I never came across such a term.

❝ The question is that whether all bioequivalence criteria (like 80-125%, group effect etc.,) are still applicable to demonstrate comparative PK.


PK means commonly modeling, which is not acceptable in BE (only NCA). That’s for good reasons (results depend on the chosen model, software/version, initial estimates, parameter constraints, convergence criteria, PopPK or two-stage approach, :blahblah:). Hence, the outcome is not necessarily reproducible.
When you decide to dive into this murky water, you will be surprised. Even for a simple one-compartment model I bet you will get a huge variability in the absorption rate constant. IMHO, 80–125% will practically never work.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,912 posts in 4,806 threads, 1,635 registered users;
26 visitors (0 registered, 26 guests [including 6 identified bots]).
Forum time: 18:22 CET (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5